Delivery Order SPE2DB22D3301-SPE2DB25FY9AY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Bosulif 100 mg tablets (120-count units) with a ceiling value of $5,704.45. This firm fixed-price delivery order is scheduled for completion by August 22, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of BOSULIF 400 mg tablets (30-count packages) with a ceiling value of $23,631.26. The contract is a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for BOSULIF 400 mg tablets (30-count) with a ceiling value of $11,815.63. The contract, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a firm fixed-price delivery order under a non-set-aside competitive procurement. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,408.90 to AmerisourceBergen Drug Corp for the supply of Bosulif 100 mg tablets (120-count units). This firm fixed-price contract, awarded on August 13, 2025, with an ultimate completion date of September 4, 2025, represents a non-set-aside, competitively awarded procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Bosulif is a prescription oncology...
- This delivery order, awarded July 28, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, provides 120 tablets of Bosulif 100 mg with a ceiling value of $5,704.45 and a firm fixed price structure. The order is scheduled for completion by August 18, 2025, and will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award represents a non-competitive delivery order issued under a larger indefinite delivery contract vehicle that...
- The U.S. Defense Department's Medical Supply Chain issued a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Bosulif 400 mg tablets in a quantity of 30 units, with a firm fixed price ceiling value of $11,815.63 and ultimate completion date of August 29, 2025. This is a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical...
- This is a Firm Fixed Price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,047.42, is to deliver 120 units of the prescription drug BOSULIF 100 mg tablets. The award has an ultimate completion date of January 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between...
- The Defense Logistics Agency awarded a delivery order valued at $5.7K to AmerisourceBergen Drug Corp for 120 tablets of Bosulif 100 mg, a tyrosine kinase inhibitor used in oncology treatment. The contract was competitively awarded without set-aside provisions under firm fixed pricing terms, with performance at the vendor's Conshohocken, Pennsylvania location and an ultimate completion date of August 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger...
- This is a $5,704.45 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of BOSULIF 100 MG TABLET 120S, a prescription medication, with a period of performance through July 23, 2025. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution company. The order is for the supply of BOSULIF 100 MG TABLET 120S, a pharmaceutical product, with a potential value of $9,982.56 and a completion date of March 26, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY9AYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Bosulif 400 mg tablets (30-count units) under a firm fixed price contract with a ceiling value of $11,815.63 and completion deadline of August 29, 2025. This is a non-set-aside, competitively awarded delivery order that represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal vendor for military and veteran healthcare systems, with performance location identified as the company's corporate office in Conshohocken, PA. This delivery order is issued under AmerisourceBergen's comprehensive DLA Troop Support Medical IDC valued at $999,999,999.00 and extending through December 2026, which enables the company to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs globally. Bosulif is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia, reflecting the company's portfolio of specialized oncology and brand-name medications supporting Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The firm fixed price structure and delivery order mechanism demonstrate the efficiency of the standing IDC vehicle in fulfilling individual pharmaceutical requirements across the military health system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 8/8/25 |